Positive News SentimentPositive NewsNASDAQ:PRCT PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis $21.21 +0.18 (+0.86%) Closing price 04:00 PM EasternExtended Trading$21.49 +0.28 (+1.32%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PROCEPT BioRobotics Stock (NASDAQ:PRCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PROCEPT BioRobotics alerts:Sign Up Key Stats Today's Range$20.21▼$21.8850-Day Range$20.60▼$29.0952-Week Range$19.35▼$62.17Volume1.41 million shsAverage Volume1.68 million shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$40.00Consensus RatingHold Company Overview PROCEPT BioRobotics, Inc. is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches. The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures. The system is designed for use in an outpatient setting, offering physicians a controlled robotic platform to carry out targeted tissue resection without the need for thermal energy. This approach is intended to minimize complications such as urinary incontinence and sexual dysfunction often associated with conventional BPH treatments. Headquartered in Redwood City, California, PROCEPT BioRobotics was founded in 2008 by Serdar Bozkurt, MD, who continues to serve as Chief Medical Officer. The AquaBeam Robotic System received U.S. Food and Drug Administration (FDA) clearance in 2016 and a CE mark for European markets, positioning the company to serve healthcare providers across North America and select international territories. PROCEPT has built a network of clinical partners and distributors to support physician training and system installation. With a focus on advancing urological care through innovation, PROCEPT BioRobotics invests in ongoing research and development to expand its platform’s capabilities and explore new indications. The company maintains collaborations with leading academic institutions and surgical centers to refine procedural protocols and gather long-term clinical data, underscoring its commitment to evidence-based adoption of robotic waterjet ablation technology.AI Generated. May Contain Errors. Read More PROCEPT BioRobotics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScorePRCT MarketRank™: PROCEPT BioRobotics scored higher than 69% of companies evaluated by MarketBeat, and ranked 173rd out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingPROCEPT BioRobotics has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 1 strong buy rating, 6 buy ratings, 7 hold ratings, and 2 sell ratings.Upside PotentialPROCEPT BioRobotics has a consensus price target of $40.00, representing about 88.6% upside from its current price of $21.21.Amount of Analyst CoveragePROCEPT BioRobotics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PROCEPT BioRobotics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.53) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PROCEPT BioRobotics is -11.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PROCEPT BioRobotics is -11.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPROCEPT BioRobotics has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PROCEPT BioRobotics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.32% of the float of PROCEPT BioRobotics has been sold short.Short Interest Ratio / Days to CoverPROCEPT BioRobotics has a short interest ratio ("days to cover") of 5.43.Change versus previous monthShort interest in PROCEPT BioRobotics has recently increased by 12.21%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPROCEPT BioRobotics does not currently pay a dividend.Dividend GrowthPROCEPT BioRobotics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment1.72 News SentimentPROCEPT BioRobotics has a news sentiment score of 1.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for PROCEPT BioRobotics this week, compared to 4 articles on an average week.Search Interest9 people have searched for PRCT on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,480.00 in company stock.Percentage Held by Insiders6.60% of the stock of PROCEPT BioRobotics is held by insiders.Percentage Held by Institutions89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PROCEPT BioRobotics' insider trading history. Receive PRCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PROCEPT BioRobotics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRCT Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Guardant Health (GH)3 hours ago | theglobeandmail.comEvercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth PotentialJune 29, 2026 | insidermonkey.comSell Tesla, Buy the New King of FSD CarsIn 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, that same stock has earned a 'Very Bullish' rating after forming a major partnership with Nvidia to power AI-driven autonomous vehicles. This barely-known company was selected to handle the complex job of getting Nvidia's self-driving AI safely inside vehicles - positioning it at the center of a massive trend most investors are still missing through Tesla.July 6 at 1:00 AM | Chaikin Analytics (Ad)Here is Why PROCEPT BioRobotics (PRCT) is Amongst the Best Robotics and Automation Names Right NowJune 25, 2026 | finance.yahoo.comIs PROCEPT BioRobotics Corporation (PRCT) A Good Stock To Buy Now?June 19, 2026 | insidermonkey.comProcept BioRobotics shares slide after Leerink downgrade cites rising competitive risksJune 12, 2026 | msn.comPROCEPT BioRobotics (NASDAQ:PRCT) EVP Sells $10,167.36 in StockJune 11, 2026 | insidertrades.comPROCEPT BioRobotics Shareholders Back Board, Pay and AuditorJune 10, 2026 | tipranks.comSee More Headlines PRCT Stock Analysis - Frequently Asked Questions How have PRCT shares performed this year? PROCEPT BioRobotics' stock was trading at $31.46 on January 1st, 2026. Since then, PRCT shares have decreased by 32.6% and is now trading at $21.21. How were PROCEPT BioRobotics' earnings last quarter? PROCEPT BioRobotics Corporation (NASDAQ:PRCT) announced its quarterly earnings data on Wednesday, April, 29th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.01. The company's quarterly revenue was up 20.1% on a year-over-year basis. Read the conference call transcript. When did PROCEPT BioRobotics IPO? PROCEPT BioRobotics (PRCT) raised $151 million in an initial public offering on Tuesday, September 14th 2021. The company issued 6,556,000 shares at a price of $22.00-$24.00 per share. Who are PROCEPT BioRobotics' major shareholders? Top institutional shareholders of PROCEPT BioRobotics include Versant Capital Management Inc. Insiders that own company stock include Frederic H Moll, Antal Rohit Desai, Reza Zadno, Kevin Waters, Morgan Colby Wood, Alaleh Nouri, Barry L Templin and Hisham Shiblaq. View institutional ownership trends. How do I buy shares of PROCEPT BioRobotics? Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PROCEPT BioRobotics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PROCEPT BioRobotics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA) and Meta Platforms (META). Company Calendar Last Earnings4/29/2026Today7/06/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (15m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 PRCT's financial health is in the Red zone, according to TradeSmith. PRCT has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:PRCT CIK1588978 Webwww.procept-biorobotics.com Phone650-232-7200FaxN/AEmployees430Year Founded2009Price Target and Rating Average Price Target for PROCEPT BioRobotics$40.00 High Price Target$70.00 Low Price Target$20.00 Potential Upside/Downside+88.6%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($1.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$95.57 million Net Margins-31.82% Pretax Margin-31.76% Return on Equity-27.70% Return on Assets-20.29% Debt Debt-to-Equity Ratio0.15 Current Ratio6.73 Quick Ratio5.51 Sales & Book Value Annual Sales$322.02 million Price / Sales3.75 Cash FlowN/A Price / Cash FlowN/A Book Value$6.55 per share Price / Book3.24Miscellaneous Outstanding Shares56,919,000Free Float47,015,000Market Cap$1.21 billion OptionableOptionable Beta0.87 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:PRCT) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PROCEPT BioRobotics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share PROCEPT BioRobotics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
